Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

20.8%

10 terminated/withdrawn out of 48 trials

Success Rate

73.0%

-13.5% vs industry average

Late-Stage Pipeline

31%

15 trials in Phase 3/4

Results Transparency

104%

28 of 27 completed trials have results

Key Signals

6 recruiting28 with results8 terminated

Enrollment Performance

Analytics

Phase 2

15(33.3%)

Phase 3

11(24.4%)

Phase 1

9(20.0%)

N/A

6(13.3%)

Phase 4

4(8.9%)

45Total

Phase 2(15)

Phase 3(11)

Phase 1(9)

N/A(6)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (48)

Showing 20 of 48 trials

NCT05810870Phase 2Active Not Recruiting

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

Role: collaborator

NCT06828848Phase 2Recruiting

A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections

Role: lead

NCT07222215Phase 2Recruiting

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Role: collaborator

NCT07159451Phase 2Recruiting

A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer

Role: collaborator

NCT06534437Phase 2Recruiting

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Role: collaborator

NCT05512364Phase 3Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

Role: collaborator

NCT03767335Phase 1Completed

MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

Role: lead

NCT06991946Recruiting

Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain

Role: collaborator

NCT04495621Phase 1Completed

MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

Role: lead

NCT03008187Phase 1Completed

MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia

Role: lead

NCT02353143Phase 1Terminated

Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia

Role: lead

NCT05532995Completed

Responses to CPET in Subjects With Persistent Exercise Intolerance After COVID-19: an Open-Source Exercise Network

Role: collaborator

NCT06174545Not ApplicableUnknown

Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma

Role: collaborator

NCT01532518Phase 2Completed

Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance

Role: lead

NCT04042077Phase 3Terminated

Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections

Role: lead

NCT03403725Phase 1Terminated

MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study

Role: lead

NCT00441350Phase 3Completed

Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension

Role: lead

NCT03605212Phase 1Terminated

Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults

Role: lead

NCT02777970Phase 4Completed

Tramadol Hydrochloride and Dexketoprofen Trometamol for the Oral Treatment of Moderate to Severe Acute Pain Following Removal of Impacted Lower Third Molar

Role: lead

NCT03327662Phase 3Terminated

Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer

Role: collaborator